Abstract
Infectious diseases in the skin represent a major group of pathologies that contribute annually for significant health economic expenses. According to WHO, Buruli Ulcer (BU) and Cutaneous Leishmaniasis (CL) are two neglected tropical diseases for which therapy remains inadequate. Topical delivery of therapeutics constitutes an advantageous alternative to treat infected skin lesions as it allows a direct treatment of affected areas avoiding unwanted systemic effects and reducing the drug dosage. However, effective topical delivery of antimicrobial agents is still a challenge. The emergence of difficult-to-treat skin mycobacteriosis such as BU or the increasing incidence of CL highlights the need for new antimicrobial agents and new delivery systems. In the present review problems related to mycobacterial and parasitic infected skin lesions will be particularly focused as well as new alternative strategies for their treatment. Currently, progresses and challenges in constructing nanocarrier platforms for delivering various antimicrobial drugs for infected skin lesions have been attempted. This article reviews the potential of these nanocarriers in the treatment of cutaneous infections, especially regarding mycobacteria and Leishmania caused skin lesions. Nanostructured biomaterials, such as lipid-based nanocarriers, have unique physicochemical properties enabling the topical application of antimicrobial drugs, thereby overcoming some of the limitations of conventional therapies. These nanosystems have been investigated for the topical delivery of well-known drugs or new therapeutic candidates. This approach is just the beginning of a stimulating nanotechnological area.
Keywords: Lipid-based nanocarriers, Topical drug delivery, Skin infections, Buruli ulcer, Cutaneous leishmaniasis, Neglected tropical diseases.
Current Pharmaceutical Design
Title:Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management
Volume: 22 Issue: 43
Author(s): Sandra Simoes, Manuela Carvalheiro and Maria Manuela Gaspar
Affiliation:
Keywords: Lipid-based nanocarriers, Topical drug delivery, Skin infections, Buruli ulcer, Cutaneous leishmaniasis, Neglected tropical diseases.
Abstract: Infectious diseases in the skin represent a major group of pathologies that contribute annually for significant health economic expenses. According to WHO, Buruli Ulcer (BU) and Cutaneous Leishmaniasis (CL) are two neglected tropical diseases for which therapy remains inadequate. Topical delivery of therapeutics constitutes an advantageous alternative to treat infected skin lesions as it allows a direct treatment of affected areas avoiding unwanted systemic effects and reducing the drug dosage. However, effective topical delivery of antimicrobial agents is still a challenge. The emergence of difficult-to-treat skin mycobacteriosis such as BU or the increasing incidence of CL highlights the need for new antimicrobial agents and new delivery systems. In the present review problems related to mycobacterial and parasitic infected skin lesions will be particularly focused as well as new alternative strategies for their treatment. Currently, progresses and challenges in constructing nanocarrier platforms for delivering various antimicrobial drugs for infected skin lesions have been attempted. This article reviews the potential of these nanocarriers in the treatment of cutaneous infections, especially regarding mycobacteria and Leishmania caused skin lesions. Nanostructured biomaterials, such as lipid-based nanocarriers, have unique physicochemical properties enabling the topical application of antimicrobial drugs, thereby overcoming some of the limitations of conventional therapies. These nanosystems have been investigated for the topical delivery of well-known drugs or new therapeutic candidates. This approach is just the beginning of a stimulating nanotechnological area.
Export Options
About this article
Cite this article as:
Simoes Sandra, Carvalheiro Manuela and Gaspar Manuela Maria, Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management, Current Pharmaceutical Design 2016; 22 (43) . https://dx.doi.org/10.2174/1381612822666160701083812
DOI https://dx.doi.org/10.2174/1381612822666160701083812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Genetics of Small-Vessel Disease
Current Medicinal Chemistry T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Strategies to Direct Angiogenesis within Scaffolds for Bone Tissue Engineering
Current Pharmaceutical Design A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study
Letters in Drug Design & Discovery Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Cardiovascular & Hematological Agents in Medicinal Chemistry Cytokine-Purine Interactions in Traumatic Stress, Behavioral Depression,and Sickness
CNS & Neurological Disorders - Drug Targets Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Current Alzheimer Research Cardiac Applications for Human Pluripotent Stem Cells
Current Pharmaceutical Design Production of Active MMP7 in E. coli and Its Application for Metalloproteinase Inhibitors Screening
Protein & Peptide Letters Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Stem Cell-based Tissue Engineering Approaches for Musculoskeletal Regeneration
Current Pharmaceutical Design Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders